ZIOPHARM ONCOLOGY INC's ticker is ZIOP and the CUSIP is 98973P101. A total of 126 filers reported holding ZIOPHARM ONCOLOGY INC in Q3 2017. The put-call ratio across all filers is 1.93 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2020 | $707,000 | -51.2% | 288,763 | -5.9% | 0.05% | -48.9% |
Q4 2019 | $1,448,000 | +24.9% | 306,786 | +13.3% | 0.09% | -10.9% |
Q3 2019 | $1,159,000 | -28.6% | 270,870 | -2.8% | 0.10% | -22.9% |
Q2 2019 | $1,624,000 | -7.8% | 278,609 | -49.4% | 0.13% | +89.9% |
Q3 2018 | $1,762,000 | -0.7% | 550,559 | -6.2% | 0.07% | -1.4% |
Q2 2018 | $1,774,000 | +1.7% | 587,255 | +46.8% | 0.07% | -1.4% |
Q1 2018 | $1,744,000 | +43.8% | 400,060 | +36.5% | 0.07% | +29.1% |
Q4 2017 | $1,213,000 | -6.4% | 293,082 | +38.8% | 0.06% | -21.4% |
Q3 2017 | $1,296,000 | +1.7% | 211,142 | +3.1% | 0.07% | -33.3% |
Q2 2017 | $1,274,000 | +45.6% | 204,744 | +48.4% | 0.10% | +20.7% |
Q1 2017 | $875,000 | +42.3% | 137,976 | +20.0% | 0.09% | +16.0% |
Q4 2016 | $615,000 | +0.5% | 114,980 | +5.8% | 0.08% | -7.4% |
Q3 2016 | $612,000 | -0.6% | 108,720 | -3.1% | 0.08% | -6.9% |
Q2 2016 | $616,000 | -44.2% | 112,156 | -24.6% | 0.09% | +27.9% |
Q1 2016 | $1,104,000 | +71.2% | 148,806 | +91.7% | 0.07% | -17.1% |
Q4 2015 | $645,000 | – | 77,605 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 9,709,607 | $60,394,000 | 3.07% |
MSD Partners, L.P. | 3,410,500 | $21,213,000 | 1.32% |
MILLER VALUE PARTNERS, LLC | 4,926,456 | $30,643,000 | 1.24% |
Michael & Susan Dell Foundation | 66,749 | $415,000 | 0.33% |
ACUTA CAPITAL PARTNERS, LLC | 150,000 | $933,000 | 0.26% |
Piermont Capital Management Inc. | 85,500 | $532,000 | 0.15% |
A.R.T. Advisors, LLC | 411,547 | $2,559,000 | 0.14% |
EQUITEC PROPRIETARY MARKETS, LLC | 96,100 | $598,000 | 0.14% |
Vident Investment Advisory, LLC | 204,744 | $1,274,000 | 0.10% |
EQUITEC PROPRIETARY MARKETS, LLC | 68,800 | $428,000 | 0.10% |